http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2563373-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b87b47407d929b7852321461253c5fa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H17-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H17-08 |
| filingDate | 2011-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f80467692dbf4472fb72c63335590d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_426de2ec2346e5b2a723de510f5f23d1 |
| publicationDate | 2013-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2563373-A1 |
| titleOfInvention | Amorphous roxithromycin composition |
| abstract | This invention relates to a macrolide composition, more particularly an amorphous form (Form-III) of 3R, 4S, 5S, 6R, 7R, 9R, 11S, 12R, 13S, 14R-6- [(2S, 3R, 4S, 6R)-4-dimethylamino-3- hydroxy-6-methyloxan-2-yl]oxy-14- ethyl-7, 12, 13-trihydroxy-4-[(2R, 4R, 5S, 6S)-5-hydroxy-4-methoxy-4, 6- dimethyloxan-2-yl]oxy-10- (2-methoxyethoxymethoxyimino) -3, 5, 7, 9, 11, 13- hexamethyl-1-oxacyclotetradecan- 2-one or roxithromycin characterised by the absence of peaks in the infra-red spectrum of amorphous (Form-Ill) of roxithromycin at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 relative to the infra-red spectrum of the prior art roxithromycin raw material displaying peaks at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 and further characterised by an increased solubility of at least 50% over prior art anhydrous and monohydrated roxithromycin in acetate buffer (pH 4.5), phosphate buffer (pH 6.8) and water. |
| priorityDate | 2010-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 94.